Search

Search Results

• DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA

  Ali Taher

  e2018066

  2018-11-01

  https://doi.org/10.4084/mjhid.2018.066

  2936

  PDF: 1597

  HTML: 237

• IRON CHELATION THERAPY IN THALASSEMIA SYNDROMES

  Paolo Cianciulli

  e2009034

  1269

  PDF: 617

  HTML: 2320

• MYELODYSPLASTIC SYNDROMES AND IRON CHELATION THERAPY

  Emanuele Angelucci, Silvana Anna Maria Urru, Federica Pilo, Alberto Piperno

  e2017021

  2017-03-01

  https://doi.org/10.4084/mjhid.2017.021

  3399

  PDF: 1296

  HTML: 1908

  Fig.1: 202

  Fig. 2: 213

• LONG-TERM EFFECTIVENESS, SAFETY, AND TOLERABILITY OF TWICE-DAILY DOSING WITH DEFERASIROX IN CHILDREN WITH TRANSFUSION-DEPENDENT THALASSEMIAS UNRESPONSIVE TO STANDARD ONCE-DAILY DOSING

  Jassada Buaboonnam, Chayamon Takpradit, Vip Viprakasit, Nattee Narkbunnam, Nassawee Vathana, Kamon Phuakpet, Kleebsabai Sanpakit, Bunchoo Pongtanakul

  e2021065

  2021-10-29

  https://doi.org/10.4084/MJHID.2021.065

  1168

  PDF: 428

  HTML: 165

• TRANSIENT ELASTOGRAPHY (TE) IS A USEFUL TOOL FOR ASSESSING THE RESPONSE OF LIVER IRON CHELATION IN SICKLE CELL DISEASE PATIENTS

  SOPHIA DELICOU

  e2018049

  2018-09-01

  https://doi.org/10.4084/mjhid.2018.049

  1557

  PDF: 828

  HTML: 193

• THERAPEUTIC VALUE OF COMBINED THERAPY WITH DEFERASIROX AND SILYMARIN ON IRON OVERLOAD IN CHILDREN WITH BETA THALASSEMIA

  adel abd elhaleim hagag

  e2013065

  2013-11-04

  https://doi.org/10.4084/mjhid.2013.065

  2652

  PDF: 835

  HTML: 14966

  Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia: 311

• IRON CHELATION THERAPY WITH DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN PRIMARY MYELOFIBROSIS

  Elena Maria Elli, Angelo Belotti, Andrea Aroldi, Matteo Parma, Pietro Pioltelli, Enrico Maria Pogliani

  e2014042

  2014-05-30

  https://doi.org/10.4084/mjhid.2014.042

  2132

  PDF: 1156

  HTML: 2009

• A Young Adult with Unintentional Acute Parenteral Iron intoxication Treated with Oral Chelation: The Use of Liver Ferriscan.

  Vincenzo De Sanctis

  e2017008

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.008

  3132

  PDF: 1020

  HTML: 1654

• ECONOMIC EVALUATION OF CHELATION REGIMENS FOR ?--THALASSEMIA MAJOR: A SYSTEMATIC REVIEW

  Jialian Li

  e2019036

  2019-06-24

  https://doi.org/10.4084/mjhid.2019.036

  2002

  PDF: 1453

  HTML: 228

• JADENU® SUBSTITUTING EXJADE® IN IRON OVERLOADED ?- THALASSEMIA MAJOR (BTM) PATIENTS: A PRELIMINARY REPORT OF THE EFFECTS ON THE TOLERABILITY, SERUM FERRITIN LEVEL, LIVER IRON CONCENTRATION AND BIOCHEMICAL PROFILES

  Vincenzo De Sanctis

  e2018064

  2018-10-27

  https://doi.org/10.4084/mjhid.2018.064

  2648

  PDF: 1218

  HTML: 262

• THE HISTORY OF DEFERIPRONE (L1) AND THE COMPLETE TREATMENT OF IRON OVERLOAD IN THALASSAEMIA The history and roles of deferiprone

  George J Kontoghiorghes, Marios Kleanthous, Christina N. Kontoghiorghe

  e2020011

  2020-01-01

  https://doi.org/10.4084/mjhid.2020.011

  2422

  PDF: 1594

  HTML: 639

• BETA THALASSEMIA MAJOR IN A DEVELOPING COUNTRY: EPIDEMIOLOGICAL, CLINICAL AND EVOLUTIONARY ASPECT

  Mohamed Bejaoui, Naouel Guirat

  e2013002

  2013-01-01

  https://doi.org/10.4084/mjhid.2013.002

  1619

  PDF: 905

  HTML: 2510

• LONGITUDINAL STUDY ON LIVER FUNCTIONS IN PATIENTS WITH THALASSEMIA MAJOR BEFORE AND AFTER DEFERASIROX (DFX) THERAPY

  Ashraf Tawfik Soliman, Mohamed Yassin, Fawzia AlYafei, Lolwa Al-Naimi, Noora Almarri, Aml Sabt, Vincenzo De Sanctis

  e2014025

  2014-04-06

  https://doi.org/10.4084/mjhid.2014.025

  2257

  PDF: 2158

  HTML: 2437

• Rhino-Orbital-Cerebral Mucormycosis after Allogeneic Hematopoietic Stem Cell Transplantation and Isavuconazole Therapeutic Drug Monitoring during Intestinal Graft versus Host Disease

  Giacomo Andreani, Gianluca Fadda, Dario Gned, Matteo Dragani, Giovanni Cavallo, Valentina Monticone, Alessandro Morotti, Marco De Gobbi, Angelo Guerrasio, Antonio D'Avolio, Daniela Cilloni

  e2019061

  2019-10-30

  https://doi.org/10.4084/mjhid.2019.061

  1428

  PDF: 1092

  HTML: 198

• NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES

  Francesco D'Alò, Mariangela Greco, Marianna Criscuolo, Maria Teresa Voso

  e2010021

  2010-08-11

  https://doi.org/10.4084/mjhid.2010.021

  1981

  PDF: 758

  HTML: 702

• ASSOCİATİON BETWEEN IRON OVERLOAD AND GLUCOSE METABOLİSM İN CHİLDREN AND YOUTH WİTH TRANSFUSİON-DEPENDENT BETA THALASSEMİA: THE ROLE OF CHELATİON THERAPY

  Deniz Guven, Dr. İncefidan, Dr. Kazanci, Dr. Ozlem Kara

  2026-02-28

  https://doi.org/10.4084/MJHID.2026.017

  658

  PDF: 544

  HTML: 72

• GLUCOSE HOMEOSTASIS AND ΑSSESSMENT OF Β-CELL FUNCTION BY 3-HOUR ORAL GLUCOSE TOLERANCE (OGTT) IN PATIENTS WITH Β-THALASSEMIA MAJOR WITH SERUM FERRITIN BELOW 1,000 NG/DL: RESULTS FROM A SINGLE ICET-A CENTRE OGTT in thalassemia and iron overload

  Vincenzo De Sanctis, Ashraf Soliman, Shahina Daar, Ploutarchos Tzoulis , Salvatore Di Maio, Christos Kattamis

  e2023006

  2023-01-01

  https://doi.org/10.4084/MJHID.2023.006

  3943

  PDF: 1114

  HTML: 460

• CARDIAC FUNCTION AND IRON CHELATION IN THALASSEMIA MAJOR AND INTERMEDIA: A REVIEW OF THE UNDERLYING PATHOPHYSIOLOGY AND APPROACH TO CHELATION MANAGEMENT

  Athanasios Aessopos, Vasilios Berdoukas

  e2009002

  2009-07-18

  1586

  PDF: 485

  HTML: 1443

• SEVERE LIVER IRON CONCENTRATIONS (LIC) IN 24 PATIENTS WITH ?-THALASSEMIA MAJOR: CORRELATIONS WITH SERUM FERRITIN, LIVER ENZYMES AND ENDOCRINE COMPLICATIONS

  Vincenzo De Sanctis

  e2018062

  2018-10-27

  https://doi.org/10.4084/mjhid.2018.062

  2648

  PDF: 1377

  HTML: 307

• PREVENTION OF ? THALASSEMIA IN NORTHERN ISRAEL - A COST-BENEFIT ANALYSIS.

  Ariel Koren, Lora Profeta, Luci Zalman, Haya Palmor, Carina Levin, Ronit Bril Zamir, Stavit Shalev, Orna Blondheim

  e2014012

  2014-02-17

  https://doi.org/10.4084/mjhid.2014.012

  2547

  PDF: 1201

  HTML: 11806

• The COST-UTILITY ANALYSIS OF FOUR CHELATION REGIMENS FOR ?-THALASSEMIA MAJOR: A CHINESE PERSPECTIVE

  Jialian Li

  e2020029

  2020-04-27

  https://doi.org/10.4084/mjhid.2020.029

  1781

  PDF: 976

  HTML: 278

• EARLY PREDICTORS OF RENAL DYSFUNCTION IN ?-THALASSEMIA MAJOR AND INTERMEDIA PATIENTS

  Azza A.G. Tantawy, Nagham El Bablawy, Amira A. M Adly, Fatma S E Ebeid

  e2014057

  2004-09-01

  https://doi.org/10.4084/mjhid.2014.057

  1961

  PDF: 951

  HTML: 3805

• ZYGOMYCOSIS IN IMMUNOCOMPROMISED NON-HAEMATOLOGICAL PATIENTS

  George Petrikkos, Miranda Drogari-Apiranthitou

  e2011012

  2011-03-14

  https://doi.org/10.4084/mjhid.2011.012

  2848

  PDF: 960

  HTML: 7344

• FASTING PLASMA GLUCOSE LEVELS WITHIN THE HIGH NORMAL RANGE ARE ASSOCIATED WITH A SIGNIFICANTLY INCREASED RISK OF FUTURE DYSGLYCEMIA IN TRANSFUSION-DEPENDENT Β THALASSEMIA: A DECADE-LONG MULTICENTER RETROSPECTIVE ANALYSIS Higher normal fasting plasma glucose and glucose dysregulation in β- thalassemia

  Vincenzo De Sanctis, Forough Saki, Mehran Karimi, Mohammad Faranoush, Ihab Elhakim, Ashraf T Soliman, Shahina Daar, Ploutarchos Tzoulis

  e2025072

  2025-10-31

  https://doi.org/10.4084/MJHID.2025.072

  649

  PDF: 249

  Html: 33

• GROWTH AND ENDOCRINE FUNCTION IN TUNISIAN THALASSEMIA MAJOR PATIENTS

  Naouel GUIRAT

  e2018031

  2018-05-01

  https://doi.org/10.4084/mjhid.2018.031

  2777

  PDF: 1017

  HTML: 422

  TABLE: 192

  FIGURES: 255

• THE DIAGNOSTIC VALUE OF PULSED WAVE TISSUE DOPPLER IMAGING IN ASYMPTOMATIC BETA- THALASSEMIA MAJOR CHILDREN AND YOUNG ADULTS ; RELATION TO CHEMICAL BIOMARKERS OF LEFT VENTRICULAR FUNCTION AND IRON OVERLOAD .

  Seham Ragab

  e2015051

  2015-08-24

  https://doi.org/10.4084/mjhid.2015.051

  1395

  PDF: 872

  HTML: 1361

  Untitled: 191

• LIVER IRON CONTENT (LIC) IN ADULTS WITH NON-TRANSFUSION DEPENDENT SICKLE CELL DISEASE (NT-SCD). CORRELATION WITH SERUM FERRITIN AND LIVER ENZYMES CONCENTRATIONS

  Vincenzo De Sanctis

  e2017037

  2017-06-20

  https://doi.org/10.4084/mjhid.2017.037

  3891

  PDF: 979

  HTML: 1152

• ASSOCIATION OF VDBP RS4701 VARIANT, BUT NOT VDR/RXR-? OVER-EXPRESSION WITH BONE MINERAL DENSITY IN PEDIATRIC ?-THALASSEMIA PATIENTS Vitamin D metabolic axis and BMD in ?-thalassemia

  Shaimaa Sahmoud, Mostafa S. Ibrahim, Eman A. Toraih, Noha Kamel, Manal Fawzy, Samar Elfiky

  e2020037

  2020-06-28

  https://doi.org/10.4084/mjhid.2020.037

  1247

  PDF: 734

  HTML: 210

• HEALTH-RELATED QUALITY OF LIFE IN THAI CHILDREN WITH THALASSEMIA AS EVALUATED BY PEDSQL AND EQ-5D-Y: A SINGLE CENTER EXPERIENCE

  Pacharapan Surapolchai, Phakatip Sinlapamongkolkul

  e2020036

  2020-06-28

  https://doi.org/10.4084/mjhid.2020.036

  1519

  PDF: 1131

  HTML: 314

• A MULTICENTER ICET-A STUDY ON AGE AT MENARCHE AND MENSTRUAL CYCLES IN PATIENTS WITH TRANSFUSION-DEPENDENT THALASSEMIA (TDT) WHO STARTED EARLY CHELATION THERAPY WITH DIFFERENT CHELATING AGENTS. Age at menarche and menstrual cycles in patients with transfusion-dependent thalassemia.

  SALVATORE DI MAIO, VINCENZO DE SANCTIS, PIERLUIGI MARZUILLO, CHRISTOS KATTAMIS, SHAHINA DAAR, MEHERAN KARIMI, SAKI FOROUGH, ATANAS BANKEV, VALERIA KALEVA, SOTEROULA CHRISTOU, CARMELO FORTUGNO, POLYXENI DELAPORTA, ASHRAF T SOLIMAN , PLOUTARCHOS TZOULIS

  e2023058

  2023-10-30

  https://doi.org/10.4084/MJHID.2023.058

  792

  PDF: 511

  HTML: 116

• VASCULAR ENDOTHELIAL GROWTH FACTOR IN CHILDREN WITH THALASSEMIA MAJOR PDF

  sameh samir fahmey, Hassan Naguib, sanna Abdelshafy, rasha Alashry

  e2013044

  2013-06-05

  https://doi.org/10.4084/mjhid.2013.044

  1325

  PDF: 868

  HTML: 1034

  Figure 1 the correlation between frequency of blood transfusion and serum vascular endothelial growth factor (VEGF).: 178

• CORRELATION OF TRANSIENT ELASTOGRAPHY WITH LIVER IRON CONCENTRATION, AND SERUM FERRITIN LEVELS IN PATIENTS WITH TRANSFUSION-DEPENDENT THALASSEMIA MAJOR PATIENTS FROM OMAN

  Hammad Khan, Vinodh Panjwani, Sara Al Rahbi, Abubakr Eltigani , Rizwan Qureshi, Khaleeq Unnisa, Najmus Sehar, Alok Mittal, Anil Pathare

  e2023048

  2023-08-29

  https://doi.org/10.4084/MJHID.2023.048

  1089

  PDF: 691

  HTML: 201

• THE ICET-A RECOMMENDATIONS FOR THE DIAGNOSIS AND MANAGEMENT OF DISTURBANCES OF GLUCOSE HOMEOSTASIS IN THALASSEMIA MAJOR PATIENTS

  Vincenzo De Sanctis

  e2016058

  2016-10-25

  https://doi.org/10.4084/mjhid.2016.058

  4242

  PDF: 1215

  HTML: 1199

• POST-LOAD PLASMA GLUCOSE INCREASE (PG-GAP) AS A RISK FACTOR FOR DEVELOPING DYSGLYCEMIA IN PATIENTS WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA (Β-TDT): RETROSPECTIVE ANALYSIS OVER 8 YEARS Post load plasma glucose increase and the risk of glucose dysregulation in thalassemia

  Vincenzo De Sanctis, Mohammad Faranoush, Efthymia Vlachaki, Theodora- Maria Venou, Ashraf T Soliman, Shahina Daar, Ploutarchos Tzoulis, Christos Kattamis

  e2025069

  2025-10-31

  https://doi.org/10.4084/MJHID.2025.069

  511

  PDF: 249

  HTML: 43

• Luspatercept Treatment in a β-Thalassemia Patient with Pulmonary Arterial Hypertension: A Case Report

  beibei yang, dongmei liu, changyu yang, Yali zhou, Guiping Liao, jian huang, Yingying Li, yinjiang tang, xiaolin yin

  e2025059

  2025-08-31

  https://doi.org/10.4084/MJHID.2025.059

  1058

  PDF: 553

  Html: 151

• DOES INSULIN LIKE GROWTH FACTOR-1 (IGF-1) DEFICIENCY HAVE A “PROTECTIVE” ROLE IN THE DEVELOPMENT OF DIABETIC RETINOPATHY IN THALASSEMIA MAJOR PATIENTS?

  Vincenzo De Sanctis

  e2015038

  2015-05-20

  https://doi.org/10.4084/mjhid.2015.038

  1972

  PDF: 935

  HTML: 5066

• Does splenectomy influence the development of Hypothyroidism in Transfusion Dependent Thalassemia Patients? A retrospective study. Splenectomy in Hypothyroidism of TDT patients

  Christos KATTAMIS, Myrto Skafida, Christalena Sofocleous, Antonis Kattamis

  e2019064

  2019-10-30

  https://doi.org/10.4084/mjhid.2019.064

  1237

  PDF: 962

  HTML: 309

• INFECTIONS IN MYELODYSPLASTIC SYNDROME IN RELATION TO STAGE AND THERAPY

  Giuseppe Leone, Livio Pagano

  e2018039

  2018-07-01

  https://doi.org/10.4084/mjhid.2018.039

  4207

  PDF: 1460

  HTML: 603

• STUDY OF SERUM HAPTOGLOBIN LEVEL AND ITS RELATION TO ERYTHROPOIETIC ACTIVITY IN BETA THALASSEMIA CHILDREN .

  Seham Ragab, Manal A. Safan, Eman A. Badr

  e2015019

  2015-02-12

  https://doi.org/10.4084/mjhid.2015.019

  2207

  PDF: 1173

  HTML: 2591

  Study of serum haptoglobin level in thalassemia: 348

  Figures: 178

• PATIENTS WITH HAEMOGLOBINOPATHIES AND CHRONIC HEPATITIS C: A REALLY DIFFICULT TO TREAT POPULATION IN 2016?

  Kalliopi Zachou, Pinelopi Arvaniti, Nikolaos K. Gatselis, Kalliopi Azariadis, Georgia Papadamou, Eirini Rigopoulou, George N. Dalekos

  e2017003

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.003

  2946

  PDF: 983

  HTML: 2065

  Cover letter: 180

• THE FREQUENCY OF ADRENAL INSUFFICIENCY IN ADOLESCENTS AND YOUNG ADULTS WITH THALASSEMIA MAJOR VERSUS THALASSEMIA INTERMEDIA IN IRAN

  Sara Matin, Masoud Ghanei Jahromi, Zohreh Karemizadeh, Sezaneh Haghpanah, Vincenzo De Sanctis, Ashraf Soliman, Mehran Karimi

  e2015005

  2014-08-28

  https://doi.org/10.4084/mjhid.2015.005

  2028

  PDF: 1077

  HTML: 9549

• BACTERIAL INFECTIONS FOLLOWING SPLENECTOMY FOR MALIGNANT AND NONMALIGNANT HEMATOLOGIC DISEASES

  Giuseppe Leone, Eligio Pizzigallo

  e2015057

  2015-10-12

  https://doi.org/10.4084/mjhid.2015.057

  4894

  PDF: 1980

  HTML: 8407

• THE PERFORMANCE OF HOMA 2 COMPARED TO DYNAMIC MARKERS OF INSULIN SECRETION AND SENSITIVITY/RESISTANCE FOR PREDICTING DYSGLYCEMIA IN TRANSFUSION-DEPENDENT Β-THALASSEMIA: THE EXPERIENCE OF A SINGLE CENTRE HOMA 2 and DYNAMIC MARKERS OF INSULIN SECRETION FOR PREDICTING DYSGLYCEMIA  in TDT

  Vincenzo De Sanctis, Shahina Daar, Ploutarchos Tzoulis, Ashraf Soliman, Ihab Elhakim , Mohammad Faranoush, Christos Kattamis

  e2026055

  2026-06-30

  https://doi.org/10.4084/MJHID.2026.056

  44

  PDF: 32

  HTML: 5

• BONE MINERAL DENSITY AND VITAMIN D RECEPTOR GENETIC VARIANTS IN EGYPTIAN CHILDREN WITH BETA THALASSEMIA ON VITAMIN D SUPPLEMENTATION

  Hadeer A Abbassy, Reham Abdel Haleem Abo Elwafa, Omneya Magdy Omar

  e2019013

  2019-01-01

  https://doi.org/10.4084/mjhid.2019.013

  2270

  PDF: 1232

  HTML: 207

• CONCISE REVIEW ON THE FREQUENCY, MAJOR RISK FACTORS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA (HCC) IN ?-THALASSEMIAS: PAST, PRESENT AND FUTURE PERSPECTIVES Thalassaemia transfusion dependent, Hepatitis C, hepatocarcinoma.

  Vincenzo De Sanctis

  e2020006

  2020-01-01

  https://doi.org/10.4084/mjhid.2020.006

  4286

  PDF: 1525

  HTML: 457

• INSULIN-LIKE GROWTH FACTOR-1 (IGF-1): DEMOGRAPHIC, CLINICAL AND LABORATORY DATA IN 120 CONSECUTIVE ADULT PATIENTS WITH THALASSAEMIA MAJOR

  V. De Sanctis

  e2014.074

  2014-11-01

  https://doi.org/10.4084/mjhid.2014.074

  2258

  PDF: 948

  HTML: 26946

• Should every patient with MDS get iron chelation – probably yes.

  Kanjaksha Ghosh, Emanuele Angelucci, Federica Pilo, Kinjalka Ghosh

  e2017055

  2017-09-01

  https://doi.org/10.4084/mjhid.2017.055

  2340

  PDF: 949

  HTML: 379

• HEMATOPOIETIC STEM CELL TRNSPLANTATION IN THALASSEMIA AND RELATED DISORDERS

  Emanuele Angelucci, Federica Pilo, Clara Targhetta, Martina Pettinau, Cristina Depau, Claudia Cogoni, Sara Usai, Mario Pani, Laura Dessì, Donatella Baronciani

  e2009015

  1415

  PDF: 491

  HTML: 3976

• A A RETROSPECTIVE LONG-TERM STUDY ON AGE AT MENARCHE AND MENSTRUAL CHARACTERISTICS IN 85 YOUNG WOMEN WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA (TDT) BORN BETWEEN 1965 AND 1995 Long-Term Study on Age at Menarche and Menstrual Characteristics in patients with TDT

  Vincenzo De Sanctis, Salvatore Di Maio

  e2021040

  2021-06-28

  https://doi.org/10.4084/MJHID.2021.040

  1528

  PDF: 498

  HTML: 181

• Late-onset male hypogonadism and fertility potential in thalassemia major patients: Two emerging issues

  Vincenzo De Sanctis

  e2015047

  2015-07-08

  https://doi.org/10.4084/mjhid.2015.047

  1806

  PDF: 935

  HTML: 804